Many cancer medications fail to effectively target the most commonly mutated cancer genes in humans, called RAS. Now, scientists have uncovered details into how normal RAS interacts with mutated RAS and other proteins in living cells for the first time. The findings could aid in the development of better RAS-targeted cancer therapeutics.
from Top Health News -- ScienceDaily https://ift.tt/2ZjTOt1
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
The IT major further said the Ebit margin for the current quarter is expected to be between 20.5-21 per cent from Home Page https://ift.tt...
-
New heat-harnessing 'solar' cells that reflect 99% of the energy they can't convert to electricity could help bring down the pri...
-
Here's a look at some of the companies whose shares are expected to trade actively in Friday's session - from Home Page http://bit...
No comments:
Post a Comment